文 献 8）Gutiérrez Rico EM, Kikuchi A, Saito T, Kumondai M, Hishinuma E, Kaneko A, et al. CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity. Drug Metab Pharmacokinet 2020; 35: 89-101. 9）Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband DG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-34.10）Trachtenberg EN, Carver JR. Stereochemistry of selenium dioxide oxidation of cyclohexenyl systems. J Org Chem 1970; 35: 1646.11）Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics 2007; 3: 211-21.12）Kisoi M, Imai M, Yamamura M, Sakaguchi Y, Murata S, Ichikawa A, et al. Unique genotyping protocol of CYP2D6 allele frequency using real time quantitative PCR from Japanese healthy women. Biol Pharm Bull 2020; 43: 904-7. 1）Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of gene variation. Pharmacol Ther 2013; 138: 103-41. 2）Lauschke VM, Ingelman-Sundberg M. Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ Genom Med 2020; 5: 9. 3）Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 Update. Clin Pharmacol Ther 2014; 95: 376-82. 4）Wollmann BM, Smith R, Kringen MK, Ingelman-Sundberg M, Molden E, Størset E. Evidence of solanidine as a dietary CYP2D6 biomarker: significant correlation with risperidone metabolism. Br J Clin Pharmacol 2023; 90: 740-7. 5）Behrle AC, Douglas J, Leeder JS, van Haandel L. Isolation and identification of 3,4-seco-solanidine-3,4-dioic acid (SSDA) as a urinary biomarker of cytochrome P450 2D6 (CYP2D6) activity. Drug Metab Dispos 2022; 50: 1342-51. 6）Iwabuchi Y. Discovery and exploitation of AZADO: the highly active catalyst for alcohol oxidation. Chem Pharm Bull (Tokyo) 2013; 61: 1197-213. 7）Sakiguchi S, Namegawa K, Nakane N, Satoh Née Okihara R, Omura K, Hagey LR, et al. 3,4-Seco-12 α -hydroxy-5 β -cholan-3,4,24-trioic acid, a novel secondary bile acid: isolation from the bile of the common ringtail possum (pseudocheirus peregrinus) and chemical synthesis. J Pharmacogn Nat Prod 2017; 3: 1000131.実臨床におけるCYP2D6活性予測バイオマーカーの有用性評価95
元のページ ../index.html#111